your addressing a very large specific market for breast cancer HER2 +1 ,+2 node negative post surgey and chemotherapy, you must try to prevent relapse rates , extend disease free survival curve, you know anyone thats had breast cancer would opt for additional vaccine benefit even if only 30% risk reduction, maybe the hedge fund shorts wives or daughters should have this issue they would use any additional adjuvants to help. Statistics are one thing the real disease condition is another. It may very well be combination of herceptin plus Neuvax gets best relapse risk reduction but you have to get it first to the market for an indication.
I agree the combo of Neuvax and Herceptin offers the best chance for patients. This particular study may
provide the glue for merging roche and galena. If neuvax work by itself is one item, neuvax plus Herceptin is the real wild card in the deck and the only reason why I am still here.